








Figure 3A




Figure 3B

3/9

pERK suppression
in AsPC-1 spheroids
Active Compound 69




Figure 4A

pERK suppression
in AsPC-1 spheroids
E3-inactive Compound 69




Figure 4B

Caspase 3/7 activity in GP2d spheroids
16 hrs




Figure 5

G12D levels and cPARP induction
G12D Compound 69
GP2d tumors




Figure 6A

Tumor PK
G12D Compound 69
GP2d tumors




Figure 6B




Figure 7A




Figure 7B




Figure 8




Figure 9A




Figure 9B




Figure 10A




Figure 10B




Figure 11




Figure 12